Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16.
Article
CAS
Google Scholar
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
Article
CAS
Google Scholar
Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–73.
Article
CAS
Google Scholar
Scobie HM, Johnson AG, Suthar AB, et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(37):1284–90.
Article
CAS
Google Scholar
Fan YJ, Chan KH, Hung IF. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3. Vaccines (Basel). 2021;9(9):989.
Article
CAS
Google Scholar
Higdon MM, Wahl B, Jones CB, et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect Dis. 2022;9(6):ofac138.
Article
Google Scholar
Gram MA, Nielsen J, Schelde AB, et al. Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose. medRxiv. 2021. https://doi.org/10.1371/journal.pmed.1003874.
Moghadas SM, Vilches TN, Zhang K, et al. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021;19(4):e3001211.
Article
CAS
Google Scholar
Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv. 2021.
Seppala E, Veneti L, Starrfelt J, et al. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. Euro Surveill. 2021;26(35):2100793.
Article
CAS
Google Scholar
Sheikh A, McMenamin J, Taylor B, Robertson C. Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2.
Article
CAS
Google Scholar
Veneti L, Seppälä E, Larsdatter Storm M, et al. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021. PLoS One. 2021;16(10):e0258513.
Article
CAS
Google Scholar
Veneti L, Valcarcel Salamanca B, Seppälä E, et al. No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway. Int J Infect Dis. 2022;115:178–84.
Article
CAS
Google Scholar
Lewis D. Mix-and-match COVID vaccines: the case is growing, but questions remain. Nature. 2021;595(7867):344–5.
Article
CAS
Google Scholar
Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346–51.
Article
CAS
Google Scholar
Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.
Article
Google Scholar
Tenbusch M, Schumacher S, Vogel E, et al. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021;21(9):1212–3.
Article
CAS
Google Scholar
Normark J, Vikstrom L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination. N Engl J Med. 2021;385(11):1049–51.
Article
CAS
Google Scholar
Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Reg Health Eur. 2021;11:100249.
Article
Google Scholar
Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. medRxiv. 2021:2021.08.24.21262423. https://doi.org/10.1056/NEJMoa2114228.
Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.
Article
CAS
Google Scholar
Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44.
Article
CAS
Google Scholar
Veneti L, Bøås H, Bråthen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Eurosurveillance. 2022;27(4):2200077.
Article
CAS
Google Scholar
Methi F, Hernæs KH, Skyrud KD, Magnusson K. Pandemic trends in health care use: From the hospital bed to self-care with COVID-19. PLOS ONE. 2022;17(3):e0265812.
Article
CAS
Google Scholar
Whittaker R, Bråthen Kristofferson A, Valcarcel Salamanca B, et al. Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin Microbiol Infect. 2022;28(6):871–8.
Article
CAS
Google Scholar
R Core Team. A language and environment for statistical computing. 2021. https://www.R-project.org/.
Therneau TM. A package for survival analysis in R, 2021. https://CRAN.R-project.org/package=survival.
Chua H, Feng S, Lewnard JA, et al. The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology. 2020;31(1):43–64.
Article
Google Scholar
Poukka E, Baum U, Palmu AA, et al. Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. medRxiv. 2021:2021.11.03.21265791. https://doi.org/10.1016/j.vaccine.2021.12.032.
Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–16.
Article
CAS
Google Scholar
Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021;26(39):2100894.
Article
CAS
Google Scholar
Lin D-Y, Gu Y, Wheeler B, et al. Effectiveness of COVID-19 vaccines in the United States over 9 months: surveillance data from the state of North Carolina. medRxiv. 2021:2021.10.25.21265304. https://doi.org/10.1056/NEJMoa2117128.
Nordström P, Ballin M, Nordström A. Effectiveness of COVID-19 vaccination against risk of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population cohort study. Hosp Death Up. 2021;9. https://doi.org/10.1016/S0140-6736(22)00089-7.
Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. N Engl J Med. 2022;386(4):340–50.
Article
CAS
Google Scholar
Fabiani M, Puopolo M, Morciano C, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe COVID-19 during predominant circulation of the Delta variant in Italy: retrospective cohort study. BMJ. 2022;376:e069052.
Article
Google Scholar
Nordstrom P, Ballin M, Nordstrom A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814–23.
Article
Google Scholar
Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208.
Article
Google Scholar
Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457–62.
Article
Google Scholar
Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. medRxiv. 2021:2021.10.26.21265397. https://doi.org/10.1093/cid/ciac290.
Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv. 2021:2021.09.15.21263583. https://doi.org/10.1056/NEJMoa2115481.
European Centre for Disease Prevention and Control. Interim public health considerations for the provision of additional COVID-19 vaccine doses, 2021. https://www.ecdc.europa.eu/en/publications-data/covid-19-public-health-considerations-additional-vaccine-doses#no-link, https://www.ecdc.europa.eu/sites/default/files/documents/Interim-public-health-considerations-for-the-provision-of-additional-COVID-19-vaccine-doses.pdf.
Tunheim G, Kran A-MB, Rø G, et al. Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in January 2021. Oslo: The Norwegian Institute of Public Health; 2021.
Google Scholar
Haber M, Halloran ME, Longini IM Jr, Watelet L. Estimation of vaccine efficacy in non-randomly mixing populations. Biometr J. 1995;37(1):25–38.
Article
Google Scholar